Solara Active Pharma Sciences Limited (BOM:541540)
India · Delayed Price · Currency is INR 499.60
+19.50 (4.06%)
At close: Feb 13, 2026
BOM:541540 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 12,547 | 12,838 | 12,889 | 14,438 | 12,683 | 16,169 |
Revenue Growth (YoY) | -4.23% | -0.40% | -10.73% | 13.84% | -21.56% | 22.33% |
Cost of Revenue | 6,394 | 6,607 | 8,629 | 8,389 | 7,079 | 7,705 |
Gross Profit | 6,153 | 6,231 | 4,261 | 6,049 | 5,605 | 8,464 |
Selling, General & Admin | 2,194 | 2,150 | 2,500 | 2,308 | 2,392 | 2,327 |
Other Operating Expenses | 2,204 | 2,008 | 2,703 | 2,353 | 2,349 | 2,205 |
Operating Expenses | 5,377 | 5,150 | 6,236 | 5,773 | 5,864 | 5,618 |
Operating Income | 775.4 | 1,081 | -1,975 | 275.9 | -259.9 | 2,846 |
Interest Expense | -908.6 | -1,094 | -1,014 | -868 | -724.2 | -803.4 |
Interest & Investment Income | 7.6 | 7.6 | 22.2 | 57.8 | 77.6 | 142.2 |
Currency Exchange Gain (Loss) | 16.4 | 16.4 | 6.7 | 2.7 | 24.2 | -16.9 |
Other Non Operating Income (Expenses) | -63.3 | -54.3 | -34.8 | -20.7 | -8.2 | -13.8 |
EBT Excluding Unusual Items | -172.5 | -43.5 | -2,995 | -552.3 | -890.5 | 2,154 |
Merger & Restructuring Charges | - | - | - | - | -34.9 | - |
Gain (Loss) on Sale of Assets | - | - | 3.6 | -4.5 | -7.7 | 20 |
Asset Writedown | - | - | -25.3 | - | - | - |
Other Unusual Items | -23.2 | 44.3 | -1,872 | 100.2 | 17.5 | 38.2 |
Pretax Income | -191.1 | 5.4 | -4,884 | -448.2 | -911 | 2,215 |
Income Tax Expense | - | - | 785.4 | -225.7 | -328.1 | 1.5 |
Earnings From Continuing Operations | -191.1 | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 |
Net Income to Company | -191.1 | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 |
Minority Interest in Earnings | - | - | -4.3 | 0.7 | 1.4 | 0.5 |
Net Income | -191.1 | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 |
Net Income to Common | -191.1 | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 |
Net Income Growth | - | - | - | - | - | 93.18% |
Shares Outstanding (Basic) | 54 | 40 | 38 | 36 | 36 | 32 |
Shares Outstanding (Diluted) | 54 | 40 | 38 | 36 | 36 | 34 |
Shares Change (YoY) | 110.38% | 4.44% | 6.13% | 0.15% | 4.75% | 28.19% |
EPS (Basic) | -3.52 | 0.14 | -148.51 | -6.16 | -16.18 | 69.00 |
EPS (Diluted) | -3.52 | 0.14 | -148.51 | -6.16 | -16.18 | 64.53 |
EPS Growth | - | - | - | - | - | 50.70% |
Free Cash Flow | - | 1,729 | 678.1 | 449.4 | -4,507 | -190.2 |
Free Cash Flow Per Share | - | 43.33 | 17.75 | 12.48 | -125.38 | -5.54 |
Dividend Per Share | - | - | - | - | - | 7.000 |
Dividend Growth | - | - | - | - | - | 250.00% |
Gross Margin | 49.04% | 48.54% | 33.06% | 41.90% | 44.19% | 52.35% |
Operating Margin | 6.18% | 8.42% | -15.33% | 1.91% | -2.05% | 17.60% |
Profit Margin | -1.52% | 0.04% | -44.02% | -1.54% | -4.58% | 13.69% |
Free Cash Flow Margin | - | 13.47% | 5.26% | 3.11% | -35.53% | -1.18% |
EBITDA | 1,685 | 2,027 | -979.8 | 1,315 | 793.3 | 3,872 |
EBITDA Margin | 13.43% | 15.79% | -7.60% | 9.11% | 6.25% | 23.95% |
D&A For EBITDA | 909.5 | 946.4 | 995.6 | 1,039 | 1,053 | 1,026 |
EBIT | 775.4 | 1,081 | -1,975 | 275.9 | -259.9 | 2,846 |
EBIT Margin | 6.18% | 8.42% | -15.33% | 1.91% | -2.05% | 17.60% |
Effective Tax Rate | - | - | - | - | - | 0.07% |
Revenue as Reported | 12,621 | 12,921 | 12,943 | 14,664 | 12,884 | 16,457 |
Advertising Expenses | - | 6.8 | 33 | 8.6 | 3.8 | 3.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.